Enzastaurin ( DrugBank: Enzastaurin )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 168 | Ehlers-Danlos syndrome | 2 |
168. Ehlers-Danlos syndrome
Clinical trials : 13 / Drugs : 21 - (DrugBank : 11) / Drug target genes : 11 - Drug target pathways : 103
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05463679 (ClinicalTrials.gov) | January 2024 | 6/4/2022 | Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome. | A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome (vEDS) Confirmed With COL3A1 Mutations, Followed by an Open Label Extension (OLE) | Vascular Ehlers-Danlos Syndrome | Drug: Enzastaurin;Drug: Placebo | Aytu BioPharma, Inc. | Parexel | Suspended | 18 Years | 60 Years | All | 260 | Phase 3 | United States |
| 2 | EUCTR2021-006574-23-NL (EUCTR) | 25/04/2022 | A study to investigate the efficacy, safety, and pharmacokinetics (PK) of enzastaurin for the prevention of arterial events in patients with vEDS confirmed with COL3A1 mutations | A multicenter, randomized, double-blind, placebo-controlled study of enzastaurin for the prevention of arterial events in patients with vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations, followed by an open label extension (OLE) - PREVEnt (Prevention of Rupture with Enzastaurin in Vascular Ehlers-Danlos Syndrome Trial) | vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations MedDRA version: 20.0;Level: PT;Classification code 10014316;Term: Ehlers-Danlos syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: Enzastaurin Product Code: AR101 INN or Proposed INN: Enzastaurin Other descriptive name: ENZASTAURIN HYDROCHLORIDE | Aytu BioPharma, Inc. | NULL | NA | Female: yes Male: yes | 260 | Phase 3 | France;United States;Belgium;Netherlands;United Kingdom;Sweden |